Epizyme, Inc. (NASDAQ:EPZM) shares have been labeled a top pick by Beta Research as it meets the A+ criteria outlined by the firm. The stock boasts a consensus analyst “Buy” rating with the consensus recommendation standing at 1.60. This is according to all covering research brokerage firms taken into consideration by First Call. The consensus price target of $23.88 also implies significant upside from the current price of $17.20.
Epizyme, Inc. (NASDAQ:EPZM) shares typically trade an average volume of 644.92 and institutions hold 98.00% of the total shares.
We see here that the stock is 3.93% away from the 20-Day Simple Moving Average. Their 50-Day Simple Moving Average is a difference of 17.17% from current levels. Further back, their 200-Day Simple Moving Average is 22.63% difference from today’s price. Currently, the stock is -8.51% from its 50-Day High and 54.26% from the 50-day low.
Epizyme, Inc. (NASDAQ:EPZM)‘s stock has performed at 42.15%. Breaking that down further, it has performed -7.77% for the week, 24.19% for the month, 26.01% over the last quarter, 0.58% for the past half-year and 93.48% for this last year.
Stock research firms currently have a positive stance on shares of QAD Inc. (NASDAQ:QADB). Analysts are projecting that the stock will reach $34.50 on a short term (1 year) basis.
The majority of analysts covering the equity have either a Buy or Strong Buy recommendation on the stock, yielding a consensus score of 1.00. This is based on the research brokerage reports taken into consideration by Thomson Reuters.
QAD Inc. (NASDAQ:QADB)’s shares may have a significant upside to the consensus target of 34.50, but how has it been performing relative to the market? The stock’s price is 28.02 and their relative strength index (RSI) stands at 62.39. RSI is a technical oscillator that shows price strength by comparing upward and downward movements. It indicates oversold and overbought price levels for a stock.
QAD Inc. (NASDAQ:QADB) shares are moving 7.36% trading at $28.02 today.